EYE. G. Yurkina

E. G. Yurkina

*This is an algorithmically generated author record based on publicly available information.

E. G. Yurkina has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Minimization of immunosuppressive therapy using mesenchymal stem cells in liver transplantation in patients with renal injury

    by S. V. Korotkov, E. G. Yurkina, A. A. Symanovich, E. A. Nazarova, I. P. Shturich, А. M. Dzyadz’kO, S. I. Krivenko, O. O. Rummo

    The aim of the study was to evaluate the possibility of using mesenchymal stem cells (MSCs) to minimize the nephrotoxic effects of tacrolimus in liver transplant recipients with high risk of developing of acute kidney injury. In a randomized prospective study, 60 patients who had undergone liver transplantation participated: 30 patients received combined MSC therapy (local intraportal and systemic intravenous administration), 30 patients received standard immunosuppressive therapy. In the MSC group, a faster recovery of graft function with an accelerated decrease in ALT on days 7 and 10 ( p < 0.05) was established with a significantly lower tacrolimus concentration at all follow-up periods (on day 14: 4.8 (2.4; 5.7) ng/ml compared to 6.3 (4.2; 8.8) ng/ml in the control group, p = 0.005). The frequency of immuno- logical graft dysfunction was 20% in both groups. However, in the MSC group exhibited a lower rejection activity index (RAI 6 (4; 7) versus 7 (4; 8) points) and no cases of humoral rejection. Analysis of the immunophenotype revealed the formation of an “immunosuppressive window” by the 4th day of the postoperative period in the MSC group, characterized by a decrease in the absolute number of CD16+56+ natural killer cells and CD3+CD4+ effector memory T-cells with an increase in the level of dendritic cells and immunosuppressive B1a-lymphocytes. The minimization of tacrolimus contributed to faster recovery of renal function with lower creatinine levels ( p < 0.05) and higher GFR values ( p < 0.05). The duration of stay in the intensive care unit and the total duration of hospitalization in the MSC group were shorter.

  • Open Access

    Mesenchymal stem cells in liver transplantation: аssessment of long-term results

    by S. V. Korotkov, E. A. Nazarova, E. G. Yurkina, В. В. Смольникова, V. Yu. Grinevich, E. A. Yanushevskaya, A. Yu. Startseva, A. E. Shcherba, S. I. Krivenko, O. O. Rummo, et al.

    Introduction. Transplantation is an effective method of treating patients with end stage liver diseases. Long-term results are determined by two main factors: the development of immunological complications and calcineurin inhibitor nephrotoxity. Application of mesenchymal stem cells (MSCs), which modulate the immune response, is a promising effective method to optimize the treatment results in patients after liver transplantation.The objective of the study was to evaluate the long-term results of mesenchymal stem cells application in liver transplantation.Material and methods. A retrospective study was performed, which included 186 patients after liver transplantation (2015–2023). The MSC group (n=93) received MSCs according to four protocols: local, systemic, combined administration, therapy for acute kidney injury; the control group (n=93) received the standard treatment. The median follow-up was 3 (2;5) years, the follow-up period being from 1-8 years. The patient survival, graft and renal function, depth of immunosuppressive therapy, anti-HLA antibody levels, and lymphocyte immunophenotype were assessed.Results. In the MSC group the incidence of immunological dysfunction of the liver allograft was decreased (22% versus 40%, pConclusion. Using MSCs in liver transplantation improves long-term outcomes by reducing the incidence of immunological complications, preserves the renal function, and reduces the need for high-dose immunosuppression.

  • Open Access

    Comparative analysis of the profile of expression of molecular markers of mesenchymal stem cells obtained from placental-umbilical cord complex tissues, adipose tissue and bone marrow

    by E. G. Yurkina, S. I. Krivenko, В. В. Смольникова, E. A. Primakova, E. A. Nazarova, A. A. Symanovich, N. I. Dedyulya, I. A. Romanova, D. Yu. Efimov, A. E. Shcherba, et al.

    Mesenchymal stem cells (MSCs) are multifunctional adult stem cells that can be derived from various tissues, such as adult adipose tissue, peripheral blood, bone marrow, neonatal placenta, and umbilical cord tissue. MSCs have the capacity for self-renewal and multidirectional differentiation. Despite the absence of differences in the expression of the main surface markers, MSCs obtained from tissues of the placenta-umbilical cord complex, adipose tissue and bone marrow differ significantly in their molecular profile. Cellular heterogeneity is ubiquitous across MSC cultures from different species and tissues. During the course of the study, the expression level of cell surface markers that characterize the heterogeneity of MSCs obtained from various sources was assessed. MSCs from all tissues express typical MSC markers on their surface, including CD13, CD73, CD105 and CD90, in the absence of expression of hematopoietic markers (CD14, CD34 and CD45), costimulatory molecules CD86, membrane protein CD154, adhesion molecules CD15, and markers of embryonic stem cells (TRA-1-81 and TRA-1-60R). However, they differed in the expression of stemness markers (October 4, Nanog), coinhibitory molecules (CD273, CD274, and CD200), cell adhesion molecules CD146, surface antigen SSEA-4, and transcription factor GATA4. The results on the molecular profile of MSCs as a heterogeneous cell population allow for the scientific substantiation of the choice of tissue source for the creation of biomedical cell products with specified therapeutic properties.

  • Open Access

    Functional characteristics of lymphocytes and plasma cytokine profile of allogeneic hematopoietic stem cell recipients as risk factors for the development of acute graft-versus-host disease

    by E. A. Prymakova, S. I. Krivenko, A. A. Symanovich, E. G. Yurkina, E. A. Nazarova, E. A. Yanushevskaya, I. N. Dedyulya, I. A. Romanova, H. Y. Startsava, N. F. Milanovich, et al.

    It has been shown that in order to identify patients with high risk for developing immunological complications after allogeneic hematopoietic stem cell transplantation (alloHSCT), it is advisable to measure quantitatively the proliferative activity of lymphocytes in alloHSCT recipients on the day of transplantation. A high donor and recipient lymphocyte stimulation index (>11.55) is an unfavorable factor in terms of development of a graft-versus-host disease (GVHD) in the early posttransplant period. In the course of the work, it was found that the study of the cytokine profile of blood plasma of alloHSC recipients in the early posttransplant period can be used as an additional method for diagnosing GVHD. The levels of IL-8 and IL-21 in the blood plasma of alloHSC recipients can act as potential biomarkers of acute GVHD.

  • Open Access

    Usage of mesenchymal cells from the human placental-umbilical complex in the correction of liver failure in patients with decompensated liver cirrhosis

    by E. G. Yurkina, D. Yu. Efimov, S. I. Krivenko, E. A. Primakova, E. A. Nazarova, A. A. Symanovich, N. I. Dedyulya, В. В. Смольникова, E. A. Yanushevskaya, I. A. Romanova, et al.

    Acute-on-chronic liver failure is an acute liver decompensation in cirrhotic patients, which leads to organ failures and high short-term mortality. The treatment is based on the management of complications and, in severe cases, liver transplantation. Liver transplantation is the most effective treatment, but the lack of donor livers and a high cost of transplantation limit its broad application. Human placenta-umbilical cord complex derived mesenchymal stem cells (MSCs) can be considered as an allogeneic source for liver disease. The aim of the study was to assess the safety and potential effectiveness of systemic administration of mesenchymal cells from the human placental-umbilical cord complex for liver failure correction in patients with decompensated cirrhosis of the liver. An open interventional prospective case-control study was conducted, including 40 patients over 18 years of age with decompensated liver cirrhosis who were hospitalized awaiting liver transplantation. Laboratory efficacy of therapy was confirmed by a significant decrease in a total bilirubin level by 39 %, an increase in total protein was noted (by 11 %), as well as stabilization of coagulopathy (decrease in INR by 25 %). Systemic administration of mesenchymal cells of placental origin is a promising therapeutic option for patients with decompensated liver cirrhosis, allowing one to increase the waiting period for emergency liver transplantation and stabilize the clinical course of the disease.